Skip to main content

4 Result(s)

within Li-Na Tang Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. No Access

    Article

    Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis

    To gain a better understanding of the overall incidence and risk of hypertension in cancer patients who receive pazopanib and to compare the differences in incidence among sorafenib, sunitinib, and pazopanib.

    Wei-**ang Qi, Feng Lin, Yuan-jue Sun, Li-Na Tang… in Cancer Chemotherapy and Pharmacology (2013)

  2. No Access

    Article

    Treatment-related mortality with aflibercept in cancer patients: a meta-analysis

    Aflibercept, a fully humanized vascular endothelial growth factor (VEGF)-targeted agent, has emerged as an effective therapy in the treatment of various solid tumors. We carried out an up-to-date meta-analysis...

    Wei-**ang Qi, Li-Na Tang, Zan Shen, Yang Yao in European Journal of Clinical Pharmacology (2014)

  3. No Access

    Article

    Risk of Hypertension in Cancer Patients Treated with Aflibercept: A Systematic Review and Meta-Analysis

    Aflibercept is currently approved as second-line treatment for patients with metastatic colorectal cancer, and its application in other types of tumors is undergoing clinical evaluation. Hypertension is one of...

    Wei-**ang Qi, Zan Shen, Li-Na Tang, Yang Yao in Clinical Drug Investigation (2014)

  4. No Access

    Article

    Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups

    The aim of this meta-analysis was to gather current data and evaluate not only the risk of gastrointestinal (GI) perforation with bevacizumab, but also the potential risk factors for this adverse event.

    Wei-**ang Qi, Zan Shen, Li-Na Tang, Yang Yao in European Journal of Clinical Pharmacology (2014)